TY - JOUR
T1 - Oncologic emergencies and urgencies
T2 - A comprehensive review
AU - Gould Rothberg, Bonnie E.
AU - Quest, Tammie E.
AU - Yeung, Sai Ching J.
AU - Pelosof, Lorraine C.
AU - Gerber, David E.
AU - Seltzer, Justin A.
AU - Bischof, Jason J.
AU - Thomas, Charles R.
AU - Akhter, Nausheen
AU - Mamtani, Mira
AU - Stutman, Robin E.
AU - Baugh, Christopher W.
AU - Anantharaman, Venkataraman
AU - Pettit, Nicholas R.
AU - Klotz, Adam D.
AU - Gibbs, Michael A.
AU - Kyriacou, Demetrios N.
N1 - Funding Information:
No external funding sources were used to support the writing of this article. Bonnie E. Gould Rothberg reports stock or stock options in Butterfly Networks Inc, Quantum Si, Hyperfine Research, AI Therapeutics, Detect Labs, Tesseract, Protein Evolution Inc, and Electric Futures outside the submitted work; in addition, her children have been employed by 4 Catalyzer; her spouse has a leadership or fiduciary role in Butterfly Networks Inc, Quantum Si, Hyperfine Research, AI Therapeutics, Detect Labs, and Tesseract; has patents planned, issued, or pending at ThermoFisher, Butterfly Networks Inc, Quantum Si, Hyperfine Research, AI Therapeutics, Detect Labs, and Tesseract; and owns stock or stock options in Butterfly Networks Inc, Quantum Si, Hyperfine Research, AI Therapeutics, Detect Labs, Tesseract, Protein Evolution Inc, Electric Futures, AbbVie, Amgen, Biocryst Pharma, Gilead, Regeneron, and Roche Holdings. Sai‐Ching J. Yeung reports research funding from Bausch Health, Bristol‐Myers Squibb, and DepoMed, Inc; personal fees from Celgene, Inc; and honoraria from Medscape outside the submitted work. David E. Gerber reports institutional grants from AstraZeneca, BerGenBio ASA, Karyopharm Pharmaceuticals, and Novocure; personal fees from Adjuvant Genomics, Regeneron Pharmaceuticals, Catalyst Pharmaceuticals, Sanofi, BeiGene LtD, Mirati Therapeutics Inc, and Janssen Scientific Affairs LLC; royalties from Oxford University Press; participation on a data safety monitoring board or advisory board for Janssen Pharmaceuticals, Regeneron, and Sanofi Aventis; and stock ownership in Gilead all outside the submitted work. Justin A. Seltzer reports long‐term stock ownership in Pfizer, Inc, outside the submitted work and is a PEER Section Editor for the American College of Emergency Physicians. Charles R. Thomas, Jr, is Deputy Editor of and . Christopher W. Baugh reports grants/research support from Visby Medical, Inc; personal fees from AcelRx Pharmaceuticals, Inc, Lucia Health Guidelines, LLC, Nabriva Therapeutics, Roche Diagnostics, and Salix Pharmaceuticals; and honoraria from Roche Diagnostics all outside the submitted work. Demetrios N. Kyriacou reports personal fees from Wellstat Therapeutics, Genetesis, and Remagine Ventures outside the submitted work. The remaining authors report no conflicts of interest. DISCLOSURES: JAMA Oncology CA: A Cancer Journal for Clinicians
Publisher Copyright:
© 2022 The Authors. CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society.
PY - 2022/11/1
Y1 - 2022/11/1
N2 - Patients with advanced cancer generate 4 million visits annually to emergency departments (EDs) and other dedicated, high-acuity oncology urgent care centers. Because of both the increasing complexity of systemic treatments overall and the higher rates of active therapy in the geriatric population, many patients experiencing acute decompensations are frail and acutely ill. This article comprehensively reviews the spectrum of oncologic emergencies and urgencies typically encountered in acute care settings. Presentation, underlying etiology, and up-to-date clinical pathways are discussed. Criteria for either a safe discharge to home or a transition of care to the inpatient oncology hospitalist team are emphasized. This review extends beyond familiar conditions such as febrile neutropenia, hypercalcemia, tumor lysis syndrome, malignant spinal cord compression, mechanical bowel obstruction, and breakthrough pain crises to include a broader spectrum of topics encompassing the syndrome of inappropriate antidiuretic hormone secretion, venous thromboembolism and malignant effusions, as well as chemotherapy-induced mucositis, cardiomyopathy, nausea, vomiting, and diarrhea. Emergent and urgent complications associated with targeted therapeutics, including small molecules, naked and drug-conjugated monoclonal antibodies, as well as immune checkpoint inhibitors and chimeric antigen receptor T-cells, are summarized. Finally, strategies for facilitating same-day direct admission to hospice from the ED are discussed. This article not only can serve as a point-of-care reference for the ED physician but also can assist outpatient oncologists as well as inpatient hospitalists in coordinating care around the ED visit.
AB - Patients with advanced cancer generate 4 million visits annually to emergency departments (EDs) and other dedicated, high-acuity oncology urgent care centers. Because of both the increasing complexity of systemic treatments overall and the higher rates of active therapy in the geriatric population, many patients experiencing acute decompensations are frail and acutely ill. This article comprehensively reviews the spectrum of oncologic emergencies and urgencies typically encountered in acute care settings. Presentation, underlying etiology, and up-to-date clinical pathways are discussed. Criteria for either a safe discharge to home or a transition of care to the inpatient oncology hospitalist team are emphasized. This review extends beyond familiar conditions such as febrile neutropenia, hypercalcemia, tumor lysis syndrome, malignant spinal cord compression, mechanical bowel obstruction, and breakthrough pain crises to include a broader spectrum of topics encompassing the syndrome of inappropriate antidiuretic hormone secretion, venous thromboembolism and malignant effusions, as well as chemotherapy-induced mucositis, cardiomyopathy, nausea, vomiting, and diarrhea. Emergent and urgent complications associated with targeted therapeutics, including small molecules, naked and drug-conjugated monoclonal antibodies, as well as immune checkpoint inhibitors and chimeric antigen receptor T-cells, are summarized. Finally, strategies for facilitating same-day direct admission to hospice from the ED are discussed. This article not only can serve as a point-of-care reference for the ED physician but also can assist outpatient oncologists as well as inpatient hospitalists in coordinating care around the ED visit.
KW - emergency medicine
KW - hematology/medical oncology
KW - internal medicine
KW - palliative care
UR - http://www.scopus.com/inward/record.url?scp=85131131953&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131131953&partnerID=8YFLogxK
U2 - 10.3322/caac.21727
DO - 10.3322/caac.21727
M3 - Review article
C2 - 35653456
AN - SCOPUS:85131131953
SN - 0007-9235
VL - 72
SP - 570
EP - 593
JO - CA Cancer Journal for Clinicians
JF - CA Cancer Journal for Clinicians
IS - 6
ER -